Centivax Inc
South San Francisco, CA · Biotech · Private
Fully-human recombinant broadly neutralizing antibodies formulated as a broad-spectrum thermostabilized antivenom (VenPen) for snakebite treatment
- Grants
- $3.2M
- 4 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 10 granted · 30 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Defense · Phase I · Development of Human Monoclonal Antibody Therapeutic against Klebsiella pneumoniae Infection | $249,939 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of World's First Fully Human Broad Spectrum Anti-Snake Venom | $995,570 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of World's First Fully Human Broad Spectrum Anti-Snake Venom | $995,570 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of World's First Fully Human Broad Spectrum Anti-Snake Venom | $996,813 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3366 | Adcendo | — | — |
| 3367 | SYNERGYS BIOTHERAPEUTICS, INC. | — | — |
| 3368 | COLLABORATIONS PHARMACEUTICALS INC | — | — |
| 3369 | Centivax Inc | — | — |
| 3370 | SPERAGEN, INC. | — | — |
| 3371 | SERVA ENERGY, INC. | — | $7.1M |
| 3372 | SwanBio Therapeutics | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Vaccine Compositions And Uses Thereofapplication
- Low Dose Vaccine Compositionsapplication
- ANTI-SARS-COV-2 Antibodies Derived From 2DD8granted
- Epitope Focusing By Variable Effective Antigen Surface Concentrationapplication
- Anti-venom Antibodies And Uses Thereofapplication
- ANTI-SARS-COV-2 Antibodies Derived From CR3022application
- Epitope Focusing By Variable Effective Antigen Surface Concentrationgranted
- Epitope Focusing By Variable Effective Antigen Surface Concentrationgranted
- Optimized Vaccine Compositions And Methods For Making The Sameapplication
- ANTI-SARS-COV-2 Antibodies Derived From 6NB6granted
- ANTI-SARS-COV-2 Antibodies Derived From CR3022granted
- ANTI-SARS-COV-2 Antibodies Derived From 2DD8granted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.